Insulet Stock-Based Compensation 2010-2025 | PODD
Insulet annual/quarterly stock-based compensation history and growth rate from 2010 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
- Insulet stock-based compensation for the quarter ending March 31, 2025 was $0.018B, a 28.17% increase year-over-year.
- Insulet stock-based compensation for the twelve months ending March 31, 2025 was $168M, a 36.14% increase year-over-year.
- Insulet annual stock-based compensation for 2024 was $0.069B, a 43.48% increase from 2023.
- Insulet annual stock-based compensation for 2023 was $0.048B, a 18.09% increase from 2022.
- Insulet annual stock-based compensation for 2022 was $0.041B, a 18.9% increase from 2021.
| Insulet Annual Stock-Based Compensation (Millions of US $) |
|
|---|---|
| 2024 | $69 |
| 2023 | $48 |
| 2022 | $41 |
| 2021 | $34 |
| 2020 | $36 |
| 2019 | $29 |
| 2018 | $38 |
| 2017 | $32 |
| 2016 | $24 |
| 2015 | $19 |
| 2014 | $23 |
| 2013 | $13 |
| 2012 | $10 |
| 2011 | $8 |
| 2010 | $5 |
| 2009 | $4 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $20.424B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $220.159B | 25.82 |
| Boston Scientific (BSX) | United States | $157.028B | 37.51 |
| Stryker (SYK) | United States | $154.023B | 32.21 |
| EssilorLuxottica (ESLOY) | France | $136.572B | 0.00 |
| Medtronic (MDT) | Ireland | $119.200B | 16.90 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.282B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.384B | 25.33 |
| ResMed (RMD) | United States | $40.346B | 30.30 |
| GE HealthCare Technologies (GEHC) | United States | $35.536B | 16.87 |
| Agilent Technologies (A) | United States | $34.139B | 22.26 |
| Terumo (TRUMY) | Japan | $25.843B | 33.57 |
| Koninklijke Philips (PHG) | Netherlands | $25.190B | 17.68 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.300B | 12.40 |
| Baxter (BAX) | United States | $14.995B | 11.19 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.871B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.189B | 25.02 |
| Lantheus Holdings (LNTH) | United States | $5.046B | 12.73 |
| Perrigo (PRGO) | Ireland | $3.908B | 9.91 |
| Prestige Consumer Healthcare (PBH) | United States | $3.799B | 16.97 |
| Haemonetics (HAE) | United States | $3.613B | 16.45 |
| Envista Holdings (NVST) | United States | $3.525B | 29.30 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.197B | 23.58 |
| LeMaitre Vascular (LMAT) | United States | $1.862B | 41.63 |
| QuidelOrtho (QDEL) | United States | $1.852B | 12.74 |
| AtriCure (ATRC) | United States | $1.559B | 0.00 |
| Acuren (TIC) | United States | $1.441B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.332B | 29.95 |
| AdaptHealth (AHCO) | United States | $1.274B | 12.93 |
| Phibro Animal Health (PAHC) | United States | $1.183B | 15.12 |
| Neogen (NEOG) | United States | $1.133B | 14.50 |
| BioLife Solutions (BLFS) | United States | $1.080B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.964B | 0.00 |
| InMode (INMD) | Israel | $0.930B | 9.38 |
| Kestra Medical Technologies (KMTS) | United States | $0.850B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.693B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.685B | 0.00 |
| Valneva SE (VALN) | France | $0.654B | 0.00 |
| Evolus (EOLS) | United States | $0.614B | 0.00 |
| Owens & Minor (OMI) | United States | $0.609B | 5.05 |
| CeriBell (CBLL) | United States | $0.547B | 0.00 |
| ZimVie (ZIMV) | United States | $0.521B | 23.70 |
| Surmodics (SRDX) | United States | $0.515B | 0.00 |
| SNDL (SNDL) | Canada | $0.398B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.359B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.336B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.324B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.323B | 11.89 |
| Capricor Therapeutics (CAPR) | United States | $0.322B | 0.00 |
| Quanterix (QTRX) | United States | $0.292B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.272B | 80.67 |
| Cerus (CERS) | United States | $0.266B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.251B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.242B | 20.40 |
| Biote (BTMD) | United States | $0.236B | 6.65 |
| Canopy Growth (CGC) | Canada | $0.234B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.230B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.227B | 0.00 |
| Omeros (OMER) | United States | $0.224B | 0.00 |
| Brainsway (BWAY) | Israel | $0.222B | 58.65 |
| Organigram Global (OGI) | Canada | $0.205B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.190B | 15.65 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.173B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.170B | 0.00 |
| Exagen (XGN) | United States | $0.155B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.135B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.121B | 0.00 |
| MacroGenics (MGNX) | United States | $0.108B | 0.00 |
| Jin Medical (ZJYL) | China | $0.102B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
| Fonar (FONR) | United States | $0.100B | 12.86 |
| Quipt Home Medical (QIPT) | United States | $0.097B | 0.00 |
| Apyx Medical (APYX) | United States | $0.096B | 0.00 |
| Safety Shot (SHOT) | United States | $0.090B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Veru (VERU) | United States | $0.082B | 0.00 |
| Zynex (ZYXI) | United States | $0.078B | 0.00 |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.060B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.059B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.29 |
| Nephros (NEPH) | United States | $0.038B | 51.00 |
| Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Senestech (SNES) | United States | $0.013B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |